Sharemaestro Newsreel

Deutsche Bank Downgrades Option Care Health to Hold From Buy, Adjusts PT to $24 From $26

Deutsche Bank has downgraded Option Care Health (OPCH) from a "Buy" rating to "Hold" and reduced its price target from $26 to $24. This action indicates a revised outlook on the stock's performance. Previously, Stephens also downgraded Option Care to "Equal Weight" from "Overweight" …

XWELL Inc. Q3 2023 Earnings: Losses Widen Sharply, Stock Declines - Dividend Growth Analysis

Prenetics (NASDAQ: PRE) updates Hong Kong risk, Bitcoin treasury

Prenetics (NASDAQ: PRE) has filed an amendment to its 2025 annual report, clarifying its holding-company structure, intra-group cash flows, non-IFRS indicators, and risks associated with Hong Kong and the PRC. The company also disclosed substantial net losses from 2023-2025 due to marketing investments for …

IQVIA Stock Climbs 25% On A 5-Day Winning Streak

IQVIA (IQV) stock has experienced a significant surge, climbing 25% over five consecutive trading days, adding $8.1 billion to its market value. This strong performance, which outpaced the S&P 500's decline during the same period, is supported by the company's slightly faster-than-market revenue growth …

Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics

A national Health Trends® study by Quest Diagnostics and Hologic, Inc. found that women testing positive for bacterial vaginosis (BV) were over three times more likely to also have non-viral sexually transmitted infections (STIs). The study, which analyzed data from 1.5 million women between …

Bacterial vaginosis patients were over 3x more likely to have an STI

A national study by Quest Diagnostics and Hologic, analyzing data from over 1.5 million U.S. women, found that 12% of women positive for bacterial vaginosis (BV) also had at least one non-viral sexually transmitted infection (STI), compared to 3.8% of BV-negative women. BV positivity …

Thermo Fisher Scientific Inc (TMO) pairs a 6.7% week with elevated volume

The diagnostics and research supplier is extending a three-month advance, though the trend screen has not turned active.

Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld …

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) reported a Q2 loss of $0.42 per share, which was worse than the Zacks Consensus Estimate of a $0.40 loss, but its revenues of $334.98 million surpassed estimates by 6.01%. Despite outperforming the market year-to-date, the stock currently holds a Zacks …

Labcorp posts Q2 revenue $3.73B, adjusted EPS $4.99; raises 2026 guidance

Labcorp reported strong second-quarter 2026 results, with revenue of $3.73 billion and adjusted diluted EPS of $4.99, marking a 14.9% year-over-year increase. The company raised its full-year 2026 guidance for both enterprise revenue growth and adjusted EPS, and announced a $1.0 billion increase in …

Icon Q1 2026 Earnings Call Transcript

ICON reported strong Q1 2026 financial results, with gross bookings up 22% year-over-year and net business wins of $2.88 billion. The company reaffirmed its full-year 2026 guidance for revenue and adjusted diluted EPS, expecting modest sequential margin improvement. Strategic investments in central labs, oncology …

Labcorp Q2 Revenue Rises 5.8 Percent to $3.73 Billion

Labcorp (LH) reported a 5.8% increase in second-quarter 2026 revenue to $3.73 billion, with diluted EPS rising to $3.64. The company raised its full-year revenue and adjusted EPS guidance and announced a $1.0 billion increase in its share repurchase authorization. Insider trading data shows …

Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance

Labcorp reported strong second-quarter 2026 results with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth. The company raised its full-year 2026 guidance, reflecting continued momentum in its business operations. Key strategic advancements include expanding oncology offerings, strengthening partnerships with health systems, …

Prenatal and Reproductive Genetic Testing Market Size & Share 2026-2035

The global prenatal and reproductive genetic testing market was valued at USD 7.8 billion in 2025 and is projected to reach USD 22.4 billion by 2035, growing at a CAGR of 11.2%. This growth is driven by increasing demand for early genetic risk assessment, …

Labcorp Holdings earnings beat by $0.20, revenue topped estimates

Labcorp Holdings (LH) reported second-quarter EPS of $4.99, exceeding analyst estimates by $0.20, and revenue of $3.73 billion, surpassing the consensus of $3.71 billion. The company also provided a positive FY 2026 EPS guidance of $18.10-$18.55, higher than the analyst consensus. Labcorp's stock has …

Revvity (RVTY) Stock Could Be 22% Undervalued As Cash Flow Supports A Bargain

Revvity's stock valuation shows a mixed picture: a Discounted Cash Flow (DCF) analysis suggests it could be 22% undervalued, implying an intrinsic value of $145 per share, while its P/E ratio of 52.9x indicates overvaluation compared to the industry average. The company's share price …

MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - WGS

Robbins Geller Rudman & Dowd LLP announces a lead plaintiff deadline of Monday, August 3, 2026, for investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false or misleading …

CareDx Number of Employees 2026 | Employee Count & Headcount Data

CareDx, Inc. (CDNA) had approximately 805 total employees worldwide as of March 2026, marking a 14.9% growth from 700 employees in 2023. The company is actively hiring, with 92 active job postings in 2026, though this represents a 28.0% decline from 2025. CareDx's workforce …

QUEST DIAGNOSTICS INC : JP MORGAN RAISES TARGET PRICE TO $250 FROM $220

JP Morgan has increased its target price for Quest Diagnostics Inc. from $220 to $250. This change in target price suggests an updated positive outlook for the company's stock by the financial institution. The specific reasons for this revised target are not detailed in …

ACHC|Acadia Healthcare Company Inc|Price:27.340|Chg%:-5.350

TradingKey provides a comprehensive stock analysis of Acadia Healthcare Company Inc (ACHC), highlighting its stable fundamentals, significant growth potential, and "fairly valued" status within the Healthcare Providers & Services industry. The report notes high institutional ownership and recent "Buy" ratings from analysts, with a …

Royal Bank of Canada Acquires 133,549 Shares of Labcorp Holdings Inc. $LH

Royal Bank of Canada increased its stake in Labcorp Holdings Inc. by 19.4%, acquiring an additional 133,549 shares, bringing its total to 820,442 shares valued at approximately $218.9 million. Labcorp surpassed quarterly earnings expectations with $4.25 EPS and $3.54 billion in revenue, leading to …

Maverick Capital Ltd. Has $426,000 Position in Labcorp Holdings Inc. $LH

Maverick Capital Ltd. significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 90.9% in the first quarter, now holding 1,596 shares valued at $426,000. Despite this reduction, Labcorp reported strong financial results, beating EPS estimates with $4.25 and growing revenue by 5.8% to …

TOI|Oncology Institute Inc|Price:4.755|Chg%:-0.195

This article provides a comprehensive stock analysis of Oncology Institute Inc (TOI), highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes a high institutional ownership and a positive outlook from analysts, with a highest …

Mettler-Toledo International, Inc. $MTD Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. decreased its holdings in Mettler-Toledo International, Inc. (NYSE:MTD) by 11.7% in the first quarter, selling 1,039 shares and retaining 7,834 shares worth $9.88 million. Other institutional investors have also adjusted their stakes, with overall institutional ownership at 95.07%. Mettler-Toledo recently reported …

Natera Inc (NTRA) Valuation: PE, PB & Fair Value Analysis

Natera Inc (NTRA) currently holds a valuation score of 9.78, placing it 3rd among 75 companies in the Healthcare Providers & Services industry. The company's P/E ratio stands at -155.99, which is significantly below its recent high and slightly above its recent low. Other …

First Trust Advisors LP Sells 23,908 Shares of Mettler-Toledo International, Inc. $MTD

First Trust Advisors LP significantly reduced its stake in Mettler-Toledo International, Inc. (MTD) by selling 23,908 shares, retaining 14,060 shares valued at approximately $17.7 million. Despite mixed analyst ratings and an average price target of $1,408.55, Mettler-Toledo exceeded quarterly earnings expectations with $8.91 EPS …

Guardant Health Inc (GH) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Guardant Health Inc (GH), detailing its volatility, financial metrics, and investment risk. The company has a beta of 1.60, indicating higher volatility compared to the S&P 500, and is ranked 72nd out of 199 in the Healthcare …

Class Action Lawsuit Filed Against GeneDx Holdings Corp. (WGS) - Recover Losses - Contact Levi & Korsinsky Before August 3, 2026

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ:WGS) by Levi & Korsinsky, LLP, on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx Holdings Corp. made false and misleading statements …

ABCL|Abcellera Biologics Inc|Price:5.715|Chg%:+0.025

This article provides a comprehensive stock analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's proprietary scoring system. ABCL's fundamentals are described as stable with high growth potential, and its valuation is considered fair within the Biotechnology & Medical Research industry. The report highlights …

Adaptive Biotechnologies Q2 Net Loss Widens Despite Revenue Growth; Stock Down

(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss amid revenue growth. In addition, the company also provided an update on its full-year 2026 revenue outlook for …

Earnings call transcript: CareDx beats Q2 2026 estimates and lifts outlook

Fulgent Genetics (FLGT) Earnings Date and Reports 2026 $FLGT

CareDx, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2026-07-30

CareDx, Inc. (CDNA) reported impressive Q2 2026 earnings, significantly beating EPS and revenue expectations. The company saw a 59.5% beat on EPS with $0.37 against an estimated $0.23, and revenue reached $132 million, surpassing the $114 million estimate by 15.7%. This strong performance was …

CareDx (NASDAQ: CDNA) swings to profit, sells lab products unit and buys Naveris

CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

ICON Public Limited Company 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ICLR) 2026-07-30

ICON reported strong Q1 2026 financial results, with gross bookings up 22% year-over-year and net business wins of $2.88 billion. The company reaffirmed its full-year 2026 guidance for revenue and adjusted diluted EPS, expecting modest sequential margin improvement. Strategic investments in central labs, oncology …